The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?
Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...
Medscape22m
Pathologic Complete Response Shows Poor Surrogacy for OS in Breast Cancer Trials
Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...